Applied Therapeutics Stock (NASDAQ:APLT)
Previous Close
$1.02
52W Range
$0.84 - $10.62
50D Avg
$6.77
200D Avg
$5.87
Market Cap
$102.40M
Avg Vol (3M)
$4.94M
Beta
2.02
Div Yield
-
APLT Company Profile
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
APLT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CGEM | Cullinan Oncology, Inc. |
| SEER | Seer, Inc. |
| BCAB | BioAtla, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| ORIC | ORIC Pharmaceuticals, Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| LTRN | Lantern Pharma Inc. |
| CCCC | C4 Therapeutics, Inc. |
| TFFP | TFF Pharmaceuticals, Inc. |
| INAB | IN8bio, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| GANX | Gain Therapeutics, Inc. |
| STTK | Shattuck Labs, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| VINC | Vincerx Pharma, Inc. |
| MOLN | Molecular Partners AG |
| LYRA | Lyra Therapeutics, Inc. |